| 000 | 04879nam a2200433 c 4500 | ||
|---|---|---|---|
| 710 | 2 |
_aSpringerLink (Online service) _9106996 |
|
| 999 |
_c117944 _d117944 _x1 |
||
| 001 | 117944 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102113835.0 | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn nnnaamaa | ||
| 008 | 191126s2019 gw a o |||| 0|eng d | ||
| 020 | _a9783030324599 | ||
| 024 | 7 |
_a10.1007/978-3-030-32459-9 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRC606.6 _b2019 EB |
|
| 100 | 1 |
_aVan Regenmortel, M. H. V. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9673829 |
|
| 245 | 1 | 0 |
_aHIVAIDS: Immunochemistry, Reductionism and Vaccine Design . _bA Review of 20 Years of Research _cby Marc H V Van Regenmortel. |
| 250 | _aFirst edition | ||
| 264 | 1 |
_aCham, Switzerland _bSpringer International Publishing _c2019 |
|
| 300 |
_a1 recurso en línea (XXVII, 364 páginas) _b20 ilustraciones, 12 ilustraciones a color |
||
| 336 |
_2rdacontent _aTexto _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_atext file _bPDF |
||
| 490 | 0 | _aBiomedical and Life Sciences (Springer-11642) | |
| 505 | 0 | _aPart I.Immunochemistry -- 1 What is a B cell epitope -- 2 Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology -- 3 Synthetic Peptide Vaccines and the Search for Neutralization B Cell Epitopes -- 4 Specificity, polyspecificity, and heterospecificity of antibody‐antigen recognition -- Part II. Reductionism -- 5 Reductionism and the search for structure-function relationships in antibody molecules -- 6 Reductionism and complexity in molecular biology -- 7 Editorial: Biological complexity emerges from the ashes of genetic reductionism -- 8 The rational design of biological complexity: A deceptive metaphor., 9 Basic research in HIV vaccinology is hampered by reductionist thinking -- 10 Commentary: Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking -- 11 Nature and Consequences of Biological Reductionism for the Immunological Study of Infectious Diseases., Part III. Vaccinology -- 12 Limitations to the structure‐based design of HIV‐1 vaccine immunogens -- 13 Two meanings of reverse vaccinology and the empirical nature of vaccine science -- 14 Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine -- 15 Paradigm Changes and the Future of HIV Vaccine Research: A Summary of a Workshop Held in Baltimore on 20 November 2013 -- 16 Editorial: Paradigm changes are required in HIV vaccine research -- 17 An outdated notion of antibody specificity is one of the major detrimental assumptions of the structure-based reverse vaccinology paradigm, which prevented it from helping to develop an effective HIV-1 vaccine -- 18 More surprises in the development of an HIV vaccine -- 19 Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine? -- 20 Old and New Concepts and Strategies in HIV Vaccinology: A Report from a Workshop held in Rome on 17 June 2016 -- 21 Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory -- 22 Immune systems rather than antigenic epitopes elicit and produce protective antibodies against HIV -- 23 Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design -- 24 Viral species, viral genomes and HIV vaccine design: is the rational design of biological complexity a utopia? | |
| 520 | 3 | _aThis book gathers a series of pivotal papers on the development of an HIV/AIDS vaccine published in the last two decades. Accompanied by extensive comments putting the material into an up-to-date context, all three parts of the book offer a broad overview of the numerous unsuccessful attempts made in recent years to develop a preventive HIV vaccine. Providing a detailed review and analysis of studies published from 1998 to the present day, it examines the likely reasons for the failure to develop an HIV vaccine despite multi-million dollar investments. | |
| 988 | _aPrimersemestre_2020_BiomedLife | ||
| 650 | 7 |
_aSIDA _2embne _xTratamiento _9140699 |
|
| 650 | 7 |
_aVIH (Virus) _9147241 _2embne _xTratamiento |
|
| 773 | 0 | _tSpringer eBooks | |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030324582 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030324605 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030324612 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-32459-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE _n0 |
||
| 998 |
_b05/2020 _dz _ea _zSI |
||